Zura Bio Limited (NASDAQ:ZURA) Given Consensus Recommendation of "Buy" by Analysts

Zura Bio Limited (NASDAQ:ZURA - Get Free Report) has received a consensus recommendation of "Buy" from the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $18.00.

A number of research firms have weighed in on ZURA. Oppenheimer reiterated an "outperform" rating and issued a $16.00 target price (down previously from $17.00) on shares of Zura Bio in a research note on Monday, April 1st. Piper Sandler began coverage on shares of Zura Bio in a research note on Friday. They issued an "overweight" rating and a $26.00 price target on the stock.

Insider Activity

In other Zura Bio news, Director Amit Munshi bought 159,744 shares of the company's stock in a transaction on Monday, April 22nd. The shares were bought at an average cost of $3.13 per share, for a total transaction of $499,998.72. Following the acquisition, the director now directly owns 777,384 shares in the company, valued at $2,433,211.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last 90 days, insiders have bought 170,926 shares of company stock worth $534,998. Company insiders own 15.80% of the company's stock.

Institutional Trading of Zura Bio

Several hedge funds and other institutional investors have recently bought and sold shares of ZURA. Armistice Capital LLC raised its position in shares of Zura Bio by 15.4% in the 4th quarter. Armistice Capital LLC now owns 1,824,000 shares of the company's stock worth $8,518,000 after acquiring an additional 244,000 shares in the last quarter. Silverarc Capital Management LLC lifted its position in shares of Zura Bio by 152.5% during the third quarter. Silverarc Capital Management LLC now owns 404,040 shares of the company's stock valued at $2,667,000 after buying an additional 244,040 shares during the last quarter. Eisler Capital US LLC bought a new stake in shares of Zura Bio in the 3rd quarter valued at about $660,000. Raymond James & Associates grew its position in shares of Zura Bio by 14.0% in the 3rd quarter. Raymond James & Associates now owns 77,356 shares of the company's stock worth $511,000 after buying an additional 9,481 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new position in shares of Zura Bio during the 3rd quarter worth approximately $224,000. Institutional investors own 61.14% of the company's stock.

Zura Bio Trading Up 6.0 %

Shares of ZURA traded up $0.26 during mid-day trading on Friday, reaching $4.62. 296,747 shares of the company's stock traded hands, compared to its average volume of 284,507. Zura Bio has a 12 month low of $2.00 and a 12 month high of $14.00. The stock's 50-day moving average is $3.24 and its two-hundred day moving average is $3.95.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.